

# WHO Drug Information

## Contents

### General Policy Issues

Wider access to HIV drugs now a reality	67
Injectable solid vaccines: a role in future immunization?	68

### Reports on Individual Drugs

Antimicrobial therapy in the management of bacterial meningitis	70
Vaccine control of Hib disease	71
WHO requirements for <i>Haemophilus influenzae</i> type b conjugate vaccines	72
Meningococcal vaccines: current status	72
Atovaquone plus proguanil effective in malaria	74
Promising approaches for a serum diagnostic test in Creutzfeldt-Jakob disease	75
Warfarin potentiated by paracetamol	75
Prevention of gastric ulcers caused by nonsteroidal anti-inflammatory drugs	76
Lymphatic filariasis: global elimination in sight	77

### Current Topics

Important breakthrough for neurovirulence testing of oral poliovirus vaccine	78
MMR vaccination: update	79
The Erice Declaration	80

### Regulatory Matters

Precipitation of carbamazepine suspension and other liquid drugs	81
Medication-associated depression	81
Plasma-derived medicinal products and Creutzfeldt-Jakob disease	81
Troglitazone-induced liver injury	81
Midazolam and paradoxical reactions in children	82
Safety of venlafaxine	82
Bromfenac and liver damage	82
Warning regarding safety of astemizole	82
Dietary supplement contains prescription medicine	83

Fenfluramine and dexfenfluramine: follow-up action	83
Sucralose: a new sweetener approved	83
Sildenafil approved to treat impotence	84
Isotretinoin-associated depression	84
Most frequently reported adverse drug reactions in Finland	84
Fexofenadine approved following terfenadine withdrawal	84
Diphtheria, tetanus and hepatitis B vaccine approved	84
Measles/mumps/rubella vaccine approved	85

### Essential Drugs

#### WHO Model Formulary:

#### Dermatological drugs (topical)

Antifungal drugs	86
Benzoic acid + salicylic acid	87
Miconazole	87
Selenium sulfide	87
Methylrosanilinium chloride	88
Sodium thiosulfate	88
Anti-infective drugs	88
Potassium permanganate	88
Neomycin + bacitracin	89
Silver sulfadiazine	89
Anti-inflammatory and antipruritic drugs	89
Betamethasone	90
Calamine lotion	90
Hydrocortisone	91
Astringents	91
Aluminium diacetate	91
Drugs affecting skin differentiation and proliferation	91
Benzoyl peroxide	92
Coal tar	93
Dithranol	93
Fluorouracil	94
Podophyllum resin	94
Salicylic acid	94
Urea	94
Scabicides and pediculicides	94
Benzyl benzoate	95
Permethrin	95
Ultraviolet blocking agents	95

.../...

---

**Contents (*continued*)****Recent Publications and Documents**

International Travel and Health	97
Guidance on the clinical investigation of medicinal products for treatment of schizophrenia	97
Draft guidance for industry: container and closure integrity testing	97
Regulatory situation of herbal plants	98

**Proposed International Nonproprietary Names: List 79** 99